Speaker:

Richard Weinshilboum, M.D., M.B.B.Ch.

Consultant - Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota

Consultant (Joint Appointment) - Division of Nephrology & Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

Full Faculty Privileges in Molec Pharm & Exper Therapeutic, Neurobiology of Disease, Biochemistry & Molecular Bio - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science

Professor of Medicine - Mayo Clinic College of Medicine and Science

Professor of Pharmacology - Mayo Clinic College of Medicine and Science

Chair - Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota

Objectives ~ upon conclusion of this program, participants should be able to:

• Examine the origins and development of pharmacogenomics from a laboratory-based science to an intergral aspect of clinical therapeutic decision making.

• Identify the challenges associated with the clinical implementation of pharmacogenomics.

• Review the technical advances and implementation strategies for pharmacogenomics in the near future.

MMI Presentation: 

Benjamin Babb, M.D. - Internal Medicine

Locations:    

• Mayo Clinic Hospital, MCH Waugh Auditorium Side A (MCH 1-220A)
• Mayo Clinic Building, Taylor Auditorium
• Mayo Clinic Primary Care, Phoenix Campus
• Mayo Clinic Women’s Health Internal Medicine
• Mayo Clinic Family Medicine – Arrowhead
• San Tan Medical Center
• Canyon Ranch Medical Center

ALL PHYSICIANS AND ALLIED STAFF ARE WELCOME

ATTENDANCE REQUIREMENT 
A unique presentation code must be sent via text to 507-200-3010 
to record attendance and to ensure you receive CME credit for your attendance.  
NOTE:  Attendees must be present to receive code.  

FACULTY DISCLOSURE

As a Jointly Accredited Provider by ACCME, ACPE, and ANCC, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.